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Many drugs exhibit variable efficacy and toxicity. Phar-
macogenetics explores the genetic underpinnings of
variable drug response. Pharmacogenetic testing is be-
ginning to enter the clinic and will have a significant
impact on the practice of clinical gastroenterology. Thio-
purine S-methyltransferase screening, which will likely
become routine for thiopurine recipients, illustrates the
promise and limitations of pharmacogenetics. Testing
for variation in other drug metabolism pathways may
also become important. Pharmacogenetics will comple-
ment but not replace traditional methods for choosing
drugs and for selecting dosing regimens for narrow-
therapeutic-index drugs.
Pharmacogenetics probes the genetics of drug re-sponse. Pharmacogenomics, often mentioned inter-
changeably with pharmacogenetics, is the genome-wide
identification of multiple drug response determinants.1
In general, a pharmacogenetic analysis considers the con-
tribution to a drug response of a small number of
genes.1,2 Clinical laboratories generally perform single-
gene analysis, so pharmacogenetics is the more appropri-
ate term for clinical drug response testing.
A fundamental pharmacogenetic concept is that a
particular drug response is influenced by a limited num-
ber of genes whose products include drug-metabolizing
enzymes, receptors, and transporters. For single-gene
testing to be useful, variation in response to a drug must
largely reflect functional differences between products of
a gene that exists in a limited number of versions, or
alleles. An individual generally has 2 identical or dis-
similar alleles for a gene—one maternal, the other pa-
ternal. In the simplest case, only 2 unique alleles for a
gene exist among a population, one encoding a fully
functional product and the other a dysfunctional prod-
uct. An individual’s gene product activity is then high,
intermediate, or low—reflecting the respective presence
of 2, 1, or 0 functional alleles. A gene is considered
polymorphic if the frequency of the low-function allele is
relatively high, generally 1% or greater.
Drug response determinants are broadly regarded as
pharmacodynamic or pharmacokinetic, although these
categories overlap. Pharmacodynamic determinants con-
trol drug target responsiveness to fixed drug concentra-
tions.3 Pharmacodynamic variation might reflect poly-
morphism among genes encoding drug receptors,
transporters, drug targets, and gene products whose ac-
tivities are central to disease progression.3,4 Genotyping
for most of these genes has yet to reach routine clinical
application. Clinical pharmacodynamic testing is routine
in 2 areas: in infectious disease, pathogen genotype (e.g.,
for hepatitis C and human immunodeficiency viruses)
may associate with therapeutic response; in oncology,
breast tumor HER2/neu expression predicts efficacy of the
anti-HER2 monoclonal antibody Herceptin (trastu-
zumab)5 and gastrointestinal stromal tumor c-Kit expres-
sion predicts response to the tyrosine kinase inhibitor
Gleevec (imatinib mesylate).6 In these instances, the
tumor or pathogen is tested but not the patient, per se;
the term pharmacogenetics generally refers to human
host variation, so tumor and pathogen genetics will not
be discussed here.
Pharmacokinetics is the study of drug or metabolite
concentrations in plasma or other tissue compartments as
a function of time and drug dose.3 Interpatient pharma-
cokinetic variation reflects differences in drug absorp-
tion, distribution, metabolism, and excretion, which
modulate availability of the drug or metabolite at target
molecules. Pharmacokinetic variation is clinically impor-
tant if it results in failure of therapeutic drug response in
some patients and/or toxic responses in others. This is
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most likely to be the case with drugs that produce benefit
without toxicity over a narrow range of blood or tissue
levels (i.e., drugs with narrow therapeutic indices).7 Re-
cent progress has identified specific enzymes and trans-
porters that underlie pharmacokinetic variability. This
review focuses upon polymorphic enzyme activities that
underlie clinically important drug responses. We have
selected examples of interest to gastroenterologists.
TPMT
The polymorphic thiopurine S-methyltransferase
(TPMT) inactivates 6-mercaptopurine (6-MP), which is
used to treat acute lymphoblastic leukemia (ALL).8 Gas-
troenterologists prescribe 6-MP and its prodrug azathio-
prine (AZA) as second-line therapy for Crohn’s disease9,10
and ulcerative colitis,11,12 in combination therapy to
prevent liver transplant rejection,13 and as treatment for
autoimmune hepatitis (AIH).14
As shown in Figure 1, AZA is nonenzymatically con-
verted to 6-MP. Xanthine oxidase (XO) then catalyzes
presystemic (first-pass) oxidation of a portion of the
6-MP pool to the inactive 6-thiouric acid.11 The 6-thio-
guanine nucleotides (6-TGNs), the active metabolites of
the unoxidized 6-MP, are downstream products of the
purine salvage enzyme hypoxanthine guanine phospho-
ribosyltransferase (HGPRT).8 TPMT produces therapeu-
tically inactive 6-methylmercaptopurine (6-MMP) and
competes with HGPRT for 6-MP substrate. XO or
TPMT activity thus limits 6-TGN production. 6-TGNs
exert therapeutic and toxic hematologic effects15 by in-
tegrating into DNA, thus interrupting replication, and
by inhibiting de novo purine synthesis.16 Hematopoietic
tissues lack XO activity and depend on TPMT to limit
6-TGN production and myelotoxicity.17 TPMT activity
can be conveniently measured radiochemically or chro-
matographically in peripheral red blood cells (RBCs).16
XO appears not to be polymorphic,18 so TPMT is the
major heritable determinant of variable thiopurine re-
sponse.
The consequences of TPMT deficiency are best defined
in pediatric ALL, for which oral 6-MP is part of remis-
sion-induction and -maintenance protocols.19 Therapeu-
tic success is tethered by serious and sometimes fatal
hematologic toxicity20 among some patients treated with
the standard ALL 6-MP dose (75 mg/m2 body surface
area per day). Toxicity associates with deficient TPMT
activity: deficient- or intermediate-activity patients are
over-represented among the thiopurine-intolerant.19,21
Low RBC TPMT activity predicts high blood 6-TGN
concentrations and high activity predicts low concentra-
tions.22,23 TPMT activity measured in RBCs or inferred
from genotype associates positively with duration of
full-dose tolerance and negatively with risk of myelosup-
pression23 and cumulative incidence of 6-MP dose reduc-
tion due to toxicity,19 i.e., lower activity confers greater
risk. TPMT assessment identifies those who should re-
ceive a reduced dose: to avoid toxicity, TPMT-deficient
ALL patients must be treated with 10-to-15-fold lower
thiopurine doses.17,19,24
TPMT activity is trimodally distributed among Cau-
casians and African-Americans (Figure 2): 89% of each
population has high activity (10 units of activity per
mL of RBCs), 11% intermediate (5 to 10 U/mL), and
0.3% low (5 U/mL; Figure 2)25; current Mayo Clinic
reference values are 15 U/mL, 6.3 to 15 U/mL, and
6.3 U/mL, respectively.26 Relative activities corre-
Figure 1. Thiopurine metabolism. Azathioprine (AZA) is non-enzymat-
ically converted to 6-mercaptopurine (6-MP), which is a substrate for
3 main competing enzymes. Hypoxanthine guanine phosphoribosyl-
transferase (HGPRT) initiates production of the active 6-thioguanine
nucleotides (6-TGNs), while xanthine oxidase (XO) and thiopurine
S-methyltransferase (TPMT) both inactivate 6-MP by converting it to
6-thiouric acid and 6-methylmercaptopurine (6-MMP), respectively.
Polymorphic TPMT activity is the major heritable determinant of vari-
able thiopurine metabolism.
Figure 2. Trimodal Distribution of TPMT Activity in RBCs. The obser-
vation of 3 groups of TPMT activity among Caucasian subjects implies
codominant inheritance. Low or deficient activity, seen among 0.3% of
subjects, represents a homozygous low-expressor genotype (TPMTL/
TPMTL); intermediate activity (11%) indicates heterozygosity (TPMTL/
TPMTH); and high activity (89%) indicates a homozygous high-expres-
sor genotype (TPMTH/TPMTH). Reprinted from Weinshilboum31 with
permission.
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spond to the respective presence of 2, 1, and 0 functional
alleles. Median activity, however, is 20% lower among
African-Americans.27 Activity distributes unimodally
among Koreans28,29 and bimodally among Chinese, who
also show a lower frequency (4%) of low or intermediate
activity.30
The bulk of TPMT variability is explained by the
variant TPMT alleles described to date.31 The *2, 3A,
*3B, *3C, *3D, *4, *5 and *6 alleles result from single
nucleotide polymorphisms (SNPs) in the TPMT gene.
The SNP underlying *4 ablates a splice site and that
causing *3D produces a premature stop codon; the rest
produce amino acid substitutions in rapidly degraded
proteins.24,32,33 As much as 90% or more of variants
among Caucasians are represented by *2, *3C, and *3A
(which results from the simultaneous presence of the *3B
and *3C SNPs).34,35 But allelic frequencies vary signifi-
cantly between populations: *3A, the most common
variant among Caucasians, is less frequent than *3C
among African-Americans and is rare among East
Asians.35,36 Promoter-region variable number tandem
repeats may also regulate TPMT expression.37
Correlation between TPMT genotype and activity is
high:16 deficiency is almost invariably explained by a
double-variant genotype and the presence of *2, *3A, or
*3C is highly sensitive (95.2%) and specific (100%) for
intermediate activity.38 Prospective genotyping may
thus identify patients at highest risk for hematologic
toxicity. But the importance of rarer alleles and other
genetic and nongenetic influences is evinced by a wide
range of activity among heterozygotes and non-variant
(wild-type) homozygotes.35 Thus, usual thiopurine dos-
ing may result in toxicity or inefficacy among low- or
high-activity patients, respectively, not identified by
genotyping.39 For this reason, some advocate measuring
RBC TPMT activity–i.e., phenotype–rather than geno-
type.
TPMT screening also predicts adverse events among
non-ALL patients. Median TPMT activity of AZA-intol-
erant AIH patients is significantly lower than that of
those in remission on AZA monotherapy (2 mg  kg1 
day1), which in turn is lower than that of those requir-
ing steroids in addition to AZA.40 TPMT-heterozygous
rheumatic disease patients treated with AZA (2–3 mg 
kg1  day1) have shown a higher incidence of leuko-
penia and a markedly lower duration of tolerated therapy
(2 vs. 39 weeks) relative to those without variant al-
leles.41 Screening may also predict inefficacy: as in ALL,31
there is the potential for undertreatment of high-TPMT
IBD patients,42 who have a lower toxicity risk but may
have a higher risk of drug failure or disease relapse.8,12
The predictive utility of TPMT genotype or pheno-
type in gastroenterology, however, is unproven. In addi-
tion to myelotoxicity, thiopurines may also cause poten-
tially dose-limiting gastrointestinal toxicities. Although
the incidence of hepatotoxicity correlates with 6-MMP
levels,19,43,44 it is not predicted by TPMT genotype.45
Among thiopurine-treated IBD patients, those with vari-
ant TPMT alleles are a minority among neutropenia
cases,43,46 indicating the importance of other factors.
Furthermore, close monitoring of transplant recipient
blood counts generally detects neutropenia in time to
adjust dosing. It is also possible to escalate dose while
monitoring for toxicity. In a “start low, go slow” ap-
proach, patients may begin AZA or 6-MP at 0.5–1.5
mg  kg1  day1 or 0.25–0.5 mg  kg1  day1,
respectively, which may be slowly increased to the main-
tenance dose,12 typically 2.0–3.0 mg  kg1  day1 for
AZA and 1.0–1.5 mg  kg1  day1 for 6-MP. Blood
counts may be measured at 2 weeks, 1 month, and 3
months and then every 3 months for the duration of
therapy.47 Treatment may be discontinued if white blood
cell counts fall below 3.0  109/L or platelets below
120  109/L.12 But this conservative approach may
result in prolonged insufficient dosing for the high-
TPMT patient majority48 and may prolong time to ther-
apeutic response, which can be delayed by up to 4
months.11 Genotype- or phenotype-specific dosing com-
bined with routine assessments such as blood counts
might allow more appropriately aggressive regimens.
As mentioned, nongenetic elements may alter appar-
ent TPMT activity and thus limit the utility of geno-
typing and predictive phenotyping. Patient age and renal
function may alter RBC TPMT activity and transfusion
within the previous 2 months may produce spurious
measurements.24 Drug interactions are also important
examples of such influences. Coadministration of AZA
and mesalamine, often the case for IBD patients, can
increase 6-TGN concentrations and raise risk of myelo-
toxicity; these interactions may reflect reversible me-
salamine inhibition of TPMT.31,49 Adverse events are
more frequent among patients treated both with thiopu-
rines and mesalamines.49,50 Therapeutic furosemide concen-
trations also inhibit TPMT.51 In contrast, thiopurine ther-
apy itself may actually increase TPMT activity.31,42,52 XO,
the other major toxicity-limiting pathway (Figure 1), is
inhibited by allopurinol11; AZA dose should be reduced by
two-thirds or more when the 2 are coprescribed.16 Metho-
trexate may augment 6-MP bioavailability by inhibiting
XO53 and may enhance cytotoxicity by inhibiting de novo
purine synthesis.39 Methotrexate may also increase levels of
phosphoribosyl pyrophosphate, an essential component of
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the HGPRT mechanism, thereby increasing entrance of
6-MP into the salvage pool.53
For these reasons, therapeutic monitoring of 6-TGN
concentrations may provide more relevant information
than does TPMT phenotype or genotype in some scenar-
ios. Higher 6-TGN levels associate with improved re-
sponse43,54 and with lower disease activity44 among pe-
diatric and adult IBD patients; nonresponders tend to
have low levels.55 Clinical efficacy associates with 6-TGN
levels higher than 250 pmol/8108 RBCs in adult co-
lonic and fistulizing CD.54 Higher levels, though, also
associate with adverse reactions.55 Thiopurine metabolite
monitoring can also elucidate the basis of non-efficacy:
low 6-TGN levels combined with high 6-MMP levels
suggest therapeutic resistance due to high TPMT activ-
ity; low 6-MMP levels may indicate noncompliance.56
The imperfect ability of TPMT genotype or phenotype
to predict clinical events suggests they will not obviate
attention to routinely assessed clinical parameters but
may be useful supplements. In October 2002, members
of the Clinical Pharmacology Subcommittee of the Ad-
visory Committee for Pharmaceutical Science (Food and
Drug Administration [FDA] Center for Drug Evaluation
and Research) recognized the inadequacy of current thio-
purine dosing guidelines and endorsed TPMT screen-
ing.57 It is thus likely that future AZA and 6-MP
product labels will include this recommendation. Failure
to screen might then entail legal liability should adverse
events occur.
CYP2D6
The hepatic drug-metabolizing enzyme cyto-
chrome P450 (CYP) 2D6 participates in the elimination
of over 100 drugs (Table 1). Individuals are classified as
CYP2D6 ultrarapid metabolizers, extensive metabolizers
(EMs), intermediate metabolizers, and poor metabolizers
(PMs) corresponding to the respective presence of at least
3 (due to gene multiplication), 2, 1, and 0 functional
alleles. CYP2D6 is not expressed in blood cells—pheno-
typing is performed by administering “probe” drugs such
as the antihypertensive debrisoquin, the oxytocic
sparteine, or the antitussive dextromethorphan. Drug
clearance or urinary metabolite-to-parent drug ratio is
then measured. Probe-based tests are still experimental
and are not commercially available.
Roughly 75 CYP2D6 alleles have been identified.58
Functional alleles include *1, *2, *9, *10, and *17. The
most common nonfunctional alleles are *3, *4, *5, and
*6. The basis for altered allele function comprises a
diversity of mechanisms that include SNPs, gene dele-
tions and multiplications, insertional mutations, and
gene conversions. Interethnic genotypic and phenotypic
frequency variations exist: PM frequency is roughly 1%
among Asian groups and 5%–10% among Caucasians.59
Also, CYP2D6 activities among genotype groups are
lower for black Africans than for whites and Asians.60
Clinical relevance for CYP2D6 polymorphism is
clearly established: PMs are more likely than EMs to
experience toxicity due to certain antiarrhythmics, anti-
depressants, and neuroleptics and are less likely to benefit
from opioid analgesics.61 For example, codeine is de-
methylated by CYP2D6 to produce morphine and causes
greater analgesia and physiologic effects in EMs than in
PMs.62,63 CYP2D6 also metabolizes the narrow-index
tricyclic antidepressants (TCAs).64 Pharmacokinetic
studies show a clear gene-dose effect for the plasma
concentration-versus-time profile of the TCA nortripty-
line. At constant dose, area-under-the-curve is highest in
subjects without functional CYP2D6 alleles and de-
creases as number of functional alleles increases.65
TCAs and selective serotonin reuptake inhibitors
(SSRIs) ameliorate functional bowel disease symptoms.
Amitryptiline is used to treat visceral hypersensitivity in
irritable bowel syndrome (IBS)66 and idiopathic fecal
Table 1. Characteristics of Specific Metabolic Pathways
Enzyme Substrates Genotypea Inducers Inhibitors Phenotyping tests
TPMT AZA, 6-MP 90% AZA, 6-MP Salicylates, furosemide RBC assay
CYP2D6 TCAs, SSRIs, codeine,
antipsychotics, nicotine,
-blockers
80% None known Fluoxetine, paroxetine,
quinidine
Dextromethorphan urine
test, sparteine urine test
CYP2C19 PPIs, proguanil,
S-mephenytoin














aPercent of genetically determined poor metabolizers identified by current genetic testing.
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incontinence.67 It is unclear whether CYP2D6 genotype
or phenotype correlates with IBS patient response to
TCAs.
As with TPMT, nongenetic factors may alter the
CYP2D6 genotype-phenotype correlation. Among the
drugs known to cause “phenocopying” to PM status are
the antiarrythmic quinidine68 and SSRIs.69 While coad-
ministration of multiple antidepressants is not generally
recommended, combined TCA-SSRI therapy can increase
TCA plasma levels in rapid metabolizers.70 This ap-
proach may improve TCA efficacy for CYP2D6 rapid-
metabolizers with depression, a common diagnosis
among IBS patients.71
Labels for several drugs suggest dose reduction for
CYP2D6 PMs but do not recommend CYP2D6 geno-
typing or phenotyping. Indeed, CYP2D6 genotyping
and phenotyping are not routinely performed in any
clinical setting due to the routine “start low, go slow”
practice of dose escalation based upon blood levels or
clinical endpoints.
CYP2C19
Polymorphic CYP2C19 activity is well described
and most humans are inferred to be CYP2C19 EMs.59
PM status is conferred by an absence of functional alleles.
Nine allelic variants have been identified to date and
designated *2A, *2B, *3, *4, *5A, *5B, *6, *7, and
*8.58 None produces a functional enzyme. Significant
interethnic differences are apparent: roughly 4%, 14%,
and 3% of blacks of African descent, Chinese individuals,
and Caucasians, respectively, are genotyped or pheno-
typed as PMs. Frequencies of PM alleles also vary sig-
nificantly between populations.59 Like CYP2D6,
CYP2C19 is not easily assayed in peripheral tissues, so
phenotype is obtained by administration of probe drugs
such as mephenytoin or omeprazole.59
Proton pump inhibitors (PPIs) are metabolized by
CYP2C19.72 Screening proponents note CYP2C19 ge-
notype association with the effects of omeprazole and
lansoprazole upon intragastric pH in H. pylori–negative
subjects73,74 and with H. pylori eradication after treat-
ment with omeprazole or lansoprazole combined with
amoxycillin and clarithromycin.75 Patients classified as
PMs by CYP2C19 genotype have the highest cure rates,
followed in order by heterozygous and homozygous EMs.
Several observations call into question the need for
CYP2C19 screening. While rates of endoscopically con-
firmed gastroesophageal reflux disease resolution associ-
ate with genotype, complete acid inhibition is achieved
in healthy subjects by frequent administration of high-
dose lansoprazole76 and H. pylori is eradicated by retreat-
ment with high-dose lansoprazole and amoxycillin,75
irrespective of genotype. Metabolism of rabeprazole, a
newer PPI, is less dependent upon CYP2C19 than is that
of older PPIs and is thus less susceptible to polymorphic
genetic effects.77 Also, greater governmental and indus-
trial interest in determinants of toxicity as opposed to
those for efficacy may dampen prospects for widespread
CYP2C19 assessment.
CYP3A
Members of the CYP3A subfamily metabolize the
majority of drugs available on the market.59,78 In adults,
the CYP3A4 and CYP3A5 isozymes are the only sub-
family members that are expressed in the liver and
intestines.79 Interindividual variation in CYP3A activity
measured with probes such as the erythromycin breath
test74 accounts largely for interpatient differences in the
pharmacokinetics of many drugs that include cyclosporin
A,80 midazolam,81 and docetaxel.82 It appears that nearly
everyone expresses CYP3A4 and a genetic basis for
marked interpatient variation in activity has not been
identified. In contrast, CYP3A5 expression is polymor-
phic and population differences abound: among some
groups (e.g., Caucasians), CYP3A5 is expressed by less
than 10% but is expressed by the majority among other
populations (e.g., African-Americans).83,84 Interpopula-
tion differences appear to reflect differences in the fre-
quency of the functional CYP3A5*1 allele. CYP3A5
expression may be greater than that of CYP3A4 in
CYP3A5-expressing individuals and CYP3A5 substrate
specificity is similar to that of CYP3A4, so it is possible
that CYP3A5 polymorphism is the major contributor to
variation in aggregate CYP3A activity.83 The clinical
implications of CYP3A5 polymorphism are largely un-
explored.
DPD
For the treatment of metastatic colorectal cancer
after surgical resection, 5-fluorouracil (5-FU) is a main-
stay.85 Dihydropyrimidine dehydrogenase (DPD), which
is encoded by the DPYD gene, is the rate-limiting
enzyme in 5-FU catabolism.86 DPD activity is at least
partially lacking in 3%–5% of people and its absence is
associated with severe toxicity and death among 5-FU-
treated cancer patients.87 DPD deficiency may largely
reflect the influence of the DPYD*2A allele, which
produces an inactive enzyme.88 While a number of ge-
netic variations have been associated with decreased DPD
activity,89,90 their population distributions and contribu-
tions to phenotypic variability have yet to be demon-
strated. It is likely that screening for multiple DPYD
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variants will be necessary in order to provide sufficient
sensitivity to testing.91
UGT1A1
The UGTs catalyze the conjugation of a variety of
drugs that include the camptothecin analogues.92 The
unconjugated hyperbilirubinemia of Gilbert’s syndrome
results mainly from deficiency of uridine diphosphate-
glucuronosyltransferase 1A1 (UGT1A1) due to a TA
insertion in the UGT1A1 promoter region that produces
the UGT1A1*28 allele.93 UGT1A1*28 has been associ-
ated with decreased glucuronidation of irinotecan’s active
and toxic metabolite SN-38 in human liver samples94
and with altered SN-38 disposition, severe neutropenia,
and diarrhea in retrospective95 and prospective studies96
of patients with various solid tumors. While Gilbert’s
syndrome is often undiagnosed in adults, it is unknown
whether UGT1A1 genotype or enzyme activity provides
useful information about patients already known to have
unconjugated hyperbilirubinemia.
Pharmacogenetics in Perspective
A widely cited meta-analysis estimates that in
1994 serious adverse drug reactions (ADRs) occurred in
2 million hospitalized patients and caused more than
100,000 fatalities, making ADRs between the fourth and
sixth leading cause of death.97 Pharmacogenetics has
been promoted as a means of reducing ADRs and drug
failures. Some have even suggested that an individual’s
relevant genetic information might be stored and used to
select optimal drugs and doses for any disease.
There are few obvious obstacles to applying genetic
technology to this end. The equipment necessary to
perform genetic testing is now available at most major
medical centers where genetic predisposition to a variety
of diseases, including hereditary hemochromatosis and
1 antitrypsin deficiency, is routinely assessed. Every
American newborn is screened for a minimum of 4
heritable diseases through analysis of a drop of blood
obtained by heel stick.98 There is thus ample precedent
in clinical medicine to screen for inherited conditions
when diagnosis is in an individual’s best interest. Screen-
ing for optimal drug response determinants is consistent
with this precedent.
Why, then, is clinical application of pharmacogenetics
only slowly occurring? The examples reviewed here dem-
onstrate the utility and limitations of pharmacogenetic
screening. One such limitation is that a gene usually has
many alleles, so that few genetic tests approach 100%
sensitivity. Furthermore, a drug’s effect may reflect the
actions of multiple metabolizing enzymes, transporters,
and targets, all of which may be polymorphically ex-
pressed. Most metabolic pathways are also affected by a
variety of nongenetic factors that include drug interac-
tions, disease, diet, and age. Thus, strong association
between a particular genotype and a drug response in
population studies does not necessarily relate the confi-
dence with which the test may predict an individual
patient’s response.
The predictive shortcomings of genotype are partially
overcome by phenotyping assays that measure the actual
target activity. But with the exception of TPMT, most
target enzymes and transporters are not present in blood
or other easily accessible tissues. Phenotyping might
therefore involve tissue biopsy or probe drug adminis-
tration. In many instances, monitoring plasma levels of
the therapeutic drug or its metabolites might be prefer-
able. This, in effect, would be the use of the drug as its
own probe. This approach generates more relevant infor-
mation than enzyme-specific probes since most drugs
have several potentially variable elimination pathways.
Pharmacokinetic diversity can therefore reflect variations
in pathways besides those targeted by a probe. Ulti-
mately, multiple-probe “cocktails” might address this
problem, but tests would need to be safe and amenable to
rapid administration and analysis to be practical for most
physicians.
The time-honored “start low, go slow” approach to
variable drug response is to monitor clinical response to
slowly escalating drug doses. This provides the advan-
tage of accounting for both pharmacokinetic and phar-
macodynamic variables. But in many instances, it may
result in prolonged intervals of ineffective treatment.
With some cancer chemotherapies, the “start low” ap-
proach may also provoke multidrug resistance.
In summary, pharmacogenetic testing will enter
mainstream clinical practice over the next decade. This
will be particularly evident in fields like psychiatry and
oncology in which many medications have narrow ther-
apeutic indices, but will probably also be evident in the
typical gastroenterology practice. When selecting a drug
and its initial dose, the patient’s relevant genotype or
pharmacokinetic/pharmacodynamic phenotype will sup-
plement but not replace traditional clinical parameters
such as age, renal function, or body size. In many cases,
current dosing paradigms such as the “start low, go slow”
approach will be modified but not abandoned.
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